The India GLP-1 receptor agonist market size was valued at USD 150.8 million in 2025 and is projected to grow from USD 240.5 million in 2026 to USD 1.00 billion by 2033, at a CAGR of 22.7% from 2026 to 2033. The market is witnessing strong expansion, driven by the rising prevalence of type 2 diabetes and obesity, alongside increasing clinical adoption of advanced incretin-based therapies. Semaglutide and dulaglutide remain the most widely prescribed molecules, supported by established efficacy in glycemic control and weight reduction benefits.
Urban healthcare centers and endocrinology-led clinics account for the majority of prescriptions, as awareness of metabolic disease management improves across Tier 1 and Tier 2 cities. Building on this expanding demand base, competitive dynamics in the India GLP-1 market are intensifying with the presence of both multinational innovators and domestic pharmaceutical companies. Novo Nordisk and Eli Lilly maintain a strong position through semaglutide and tirzepatide offerings, particularly in premium urban segments. At the same time, Indian companies such as Sun Pharma, Dr. Reddy’s Laboratories, Cipla, and Biocon are actively strengthening their presence through biosimilar development and anticipated post-patent entry strategies. This competitive environment is expected to significantly reshape pricing structures, especially as semaglutide patent protections approach expiry in India.
The India GLP-1 receptor agonist market is expected to transition toward broader accessibility and volume-driven growth, particularly in the post-patent period. Tirzepatide is emerging as a key growth driver due to its dual GIP and GLP-1 mechanism, offering enhanced weight-loss outcomes compared to traditional therapies. Meanwhile, expanding awareness of obesity as a chronic disease is gradually increasing uptake beyond diabetes-focused treatment, particularly in urban private-pay segments. Price reductions anticipated from generic semaglutide entries are expected to further accelerate market penetration across Tier 2 and Tier 3 cities. Overall, the market is evolving from a specialist-driven niche therapy space into a more mainstream metabolic treatment category, supported by stronger physician adoption, improving affordability, and widening patient eligibility across India’s healthcare system.
This product will be delivered within 1-3 business days.
Urban healthcare centers and endocrinology-led clinics account for the majority of prescriptions, as awareness of metabolic disease management improves across Tier 1 and Tier 2 cities. Building on this expanding demand base, competitive dynamics in the India GLP-1 market are intensifying with the presence of both multinational innovators and domestic pharmaceutical companies. Novo Nordisk and Eli Lilly maintain a strong position through semaglutide and tirzepatide offerings, particularly in premium urban segments. At the same time, Indian companies such as Sun Pharma, Dr. Reddy’s Laboratories, Cipla, and Biocon are actively strengthening their presence through biosimilar development and anticipated post-patent entry strategies. This competitive environment is expected to significantly reshape pricing structures, especially as semaglutide patent protections approach expiry in India.
The India GLP-1 receptor agonist market is expected to transition toward broader accessibility and volume-driven growth, particularly in the post-patent period. Tirzepatide is emerging as a key growth driver due to its dual GIP and GLP-1 mechanism, offering enhanced weight-loss outcomes compared to traditional therapies. Meanwhile, expanding awareness of obesity as a chronic disease is gradually increasing uptake beyond diabetes-focused treatment, particularly in urban private-pay segments. Price reductions anticipated from generic semaglutide entries are expected to further accelerate market penetration across Tier 2 and Tier 3 cities. Overall, the market is evolving from a specialist-driven niche therapy space into a more mainstream metabolic treatment category, supported by stronger physician adoption, improving affordability, and widening patient eligibility across India’s healthcare system.
India GLP-1 Receptor Agonist Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the India GLP-1 receptor agonist market report based on product, application, route of administration, and distribution channel:Product Outlook (Revenue, USD Million, 2021-2033)
- Semaglutide (Ozempic, Wegovy, Rybelsus)
- Tirzepatide (Mounjaro, Zepbound)
- Dulaglutide (Trulicity)
- Liraglutide (Victoza, Saxenda)
- Others (Byetta, Bydureon, SOLIQUA)
Application Outlook (Revenue, USD Million, 2021-2033)
- Type 2 Diabetes Mellitus
- Obesity / Chronic Weight Management
- Cardiovascular Risk
Route of Administration Outlook(Revenue, USD Million, 2021-2033)
- Injectable / Parenteral
- Oral
Distribution Channel Outlook (Revenue, USD Million, 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. India GLP-1 Receptor Agonist Market Variables, Trends, & Scope
Chapter 4. India GLP-1 Receptor Agonist Market: Product Business Analysis
Chapter 5. India GLP-1 Receptor Agonist Market: Application Business Analysis
Chapter 6. India GLP-1 Receptor Agonist Market: Route of Administration Business Analysis
Chapter 7. India GLP-1 Receptor Agonist Market: Distribution Channel Business Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Novo Nordisk A/S
- Eli Lilly and Company
- Sun Pharmaceutical Industries Ltd
- Dr. Reddy’s Laboratories Ltd
- Zydus Lifesciences
- Lupin Limited
- Torrent Pharmaceuticals Ltd
- Cipla Limited
- Emcure Pharmaceuticals Ltd
- Abbott Laboratories
